X4 Pharmaceuticals (XFOR) Misses Q2 EPS by 17c
Tweet
Share
E-mailGet Alerts XFOR Hot Sheet
Join SI Premium – FREE
X4 Pharmaceuticals (NASDAQ: XFOR) reported Q2 EPS of ($0.33), $0.17 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $-55.7 million.
For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Kura Sushi (KRUS) Tops Q3 EPS by 3c; offers outlook
- Goldman Sachs Starts Banco de Sabadell SA (SAB:SM) (BNDSF) at Sell
- ExxonMobil outlines key factors for Q2 2026 earnings outlook
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
